Effects of human tissue kallikrein gene A1789G polymorphism on plasma creatinine levels in patients with essential hypertension

Abstract

Abstract: AIM: To investigate the effect of the human tissue kallikrein gene (hKLK1) polymorphism on plasma creatinine levels in hypertensive subjects. METHODS: The hKLK1 A1789G polymorphism was genotyped by PCR-restriction fragment length polymorphism (RFLP) in 733 hypertensive subjects. The relationship between genotype and plasma creatinine level was performed by a multiple regression analysis. The interactive effect of genotype and blood pressure on the plasma creatinine level was accessed by ANOVA. RESULTS: Multiple regression analysis showed that the plasma creatinine level was significantly higher in the subjects with mutant allele G (AG or GG genotype) than in those with wild allele A (AA genotype) (P =0.009 and P = 0.046, respectively). ANOVA indicated that the AG and GG genotype individuals had high plasma creatinine levels in SBP and DBP Compared with AA genotype individuals, and the plasma creatinine level increased with blood pressure rises (P <0.05). CONCLUSION: The hKLK1 A1789G polymorphism influences plasma creatinine level, and the A1789→G variation is a risk factor in renal plasma creatinine clearance rate decline in hypertensive individuals.

Key words: tissue kallikrein, gene polymorphism, plasma creatinine, hypertension, PCR-RFLP

CLC Number:

R966

HONG Zong-yuan, ZHANG Xiu-qing, HUANG Guo, LING Dai-jun, XU Xi-ping. Effects of human tissue kallikrein gene A1789G polymorphism on plasma creatinine levels in patients with essential hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(6): 637-641.

References

1 Meneton P, Bloch-Faure M, Hagege AA, Ruetten H, Huang W, Bergaya S, et al.Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice[J]. Proc Natl Acad Sci U S A, 2001;98: 2634-9
2 Xiong W, Chao J, Chao L.Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats[J]. Hypertension, 1995;25: 715-9
3 Bhoola KD, Figueroa CD, Worthy K.Bioregulation of kinins: kallikreins, kininogens and kininases [J]. Pharmacol Rev, 1992;44:1-80
4 Yu H, Song Q, Freedman BI, Chao J, Chao L, Rich SS, et al.Association of the tissue kallikrein gene promoter with ESRD and hypertension[J]. Kidney Int, 2002; 61:1030-9
5 Elliot R, Nuzum FR. Urinary excretion of a depressor substance (kallikrein of frey and kraut) in arterial hypertension[J]. Endocrinology, 1934; 18:462-74
6 Carretero OA, Polomski C, Hampton A, Scicli AG. Urinary kallikrein, plasma renin and aldosterone in New Zealand genetically hypertensive (GH) rats[J]. Clin Exp Pharmacol Physiol, 1976;3:55-9
7 Carretero OA, Amin VM, Ocholik T, Scicli AG, Koch J. Urinary kallikrein in rats bred for their susceptibility and resistance to the hypertensive effect of salt. A new radioimmunoassay for its direct determination[J]. Circ Res, 1978;42:727-31
8 Ader JL, Tran-Van T, Praddaude F.Low urinary excretion of active and total kallikrein in developing spontaneously hypertensiverats and effect of long term converting enzyme inhibition[J]. Agents Actions Suppl, 1987; 22:329-38
9 Ader JL, Tran-Van T, Praddaude F.Renal tissue kallikrein in newborn and young SHR[J]. Am J Hypertens, 1987; 1: S53-5
10 Williams RR, Hunt SC, Wu LL, Hasstedt ST, Barlow GK, Stults BM, et al. Early pathogenesis of primary hypertension: biological markers of genetically predisposed hypertension[M]. Amsterdam:Elsevier Science Publishing, 1987
11 Wolf WC, Harley RA, Sluce D, Chao L, Chao J.Localization and expression of tissue kallikrein and kallistatin in human blood vessels[J]. J Histochem Cytochem, 1999;47: 221-8
12 Margolis HS, Geller R, Pisano JJ, Sjoerdsma A.Altered urinary kallikrein excretion in human hypertension[J]. Lancet; 1971; 2:1063-5
13 Zinner SH, Margolius HS, Rosner B, Kass EH.Stability of blood pressure rank and urinary kallikrein concentration in childhood:an eight-year follow-up[J]. Circulation, 1978;58: 908-15
14 Overlack A, Stumpe KO, Kolloch R, Ressel C, Krueck F. Antihypertensive effect of orally administered glandular kallikrein in essential hypertension.Results of double blind study [J]. Hypertension, 1981;3: I18-21
15 Ogawa K, Ito T, Ban M, Mochizuki M, Satake T.Effects of orally administered glandular kallikrein on urinary kallikrein and prostaglandin excretion, plasma immunoreactive prostanoids and platelet aggregation in essential hypertension[J]. KlinWochenschr, 1985; 63:332-6
16 Pravence M, Ken V, Kunes J, Carretero OA, Simonet L, Kurtz TW.Cosegregation of blood pressure with a kallikrein gene family polymorphism[J]. Hypertension, 1991;17:242-6
17 Woodley-Miller C, Chao J, Chao L.Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes[J]. J Hypertens, 1989;7: 865-71
18 Wang J, Xiong W, Yang Z, Davis T, Dewey MJ, Chao J, et al.Human tissue kallikrein induces hypotension in transgenic mice[J]. Hypertension, 1994; 23:236-43
19 Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash O, et al.A gene for high urinary kallikrein may protect against hypertension in Utah kindreds[J]. Hypertension, 1989; 13:3-8
20 Slim R, Torremocha F, Moreau T, Pizard A, Hunt SC, Vuagnat A, et al.Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity[J]. J Am Soc Nephrol, 2002;13:968-76
21 Berge KE, Bakken A, Bohn M, Erikssen J, Berg K.Analy ses of mutations in the human renal kallikrein (hKLK1) gene and their possible relevance to blood pressure regulation and risk of myocardial infarction[J]. Clin Genet, 1997;52:86-95
22 Evans BA, Yun ZX, Close JA, Tregear GW, Kitamura N, Nakanishi S, et al.Structure and chromosomal localization of the human renal kallikrein gene[J]. Biochemistry, 1988; 27: 3124-9
23 Granger JP, Hall JE.Acute and chronic actions of bradykinin on renal function and arterial pressure[J]. Am J Physiol, 1985;248:F87-92

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[4]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[5]	SHEN Chang, AI Kelong, HU Changping. Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
[6]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[7]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[8]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[9]	ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
[10]	CUI Sumei, CUI Zhaoqiang. Application of β-blockers for hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.
[11]	LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
[12]	XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
[13]	KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng. Angiotensin receptor neprilysin inhibitor in elderly with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.
[14]	LIU Guijian, CHENG Kuan, ZHU Wenqing, GE Junbo. Progress of hypertension pharmacological treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 446-449.
[15]	MENG Shi, WANG Zhongqun. Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.